Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

$ENTB Stem Cell Working To Treat Pets Cancer/Arthritis Update & FORM 8-K - CURRENT REPORT

$ENTB Stem Cell Working to Treat Pets Cancer/Arthritis

Thoroughbred (EIPH)


Zander Therapeutics is a Subsidiary of Entest Biomedical, Inc. - Regen BioPharma, Inc. (OTCQB:RGBP) is the Parent of Entest (ENTB-OTC)

RGBP has licensed various items to ENTB-NR2F6 being a Primary Focus.

NR2F6 is the Key to Zanders Success-Working Clinically to Treat Pets for Cancer/Arthritis - Thoroughbred Race Horses for (EIPH)

$ENTB has Shown Great Results - Silencing/Killing Cancer Cells Using Pets Own Blood

Other Recent News - Entest BioMedical's Chairman Discusses its Subsidiary, Zander Therapeutics, Inc.'s Progress with Small Molecule Immunotherapies for Treating Cancer and Arthritis in Dogs

Read More:

Read More-

Great News -Further Advancement-Treating Cancer-Auto Immune Diseases-Lupus

Robert Kreh - Principal

Small Cap Solutions, LLC

(443) 567-2609

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.